Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.67 |
| ▸ | NPC1 | O15118 | 9/20 | 0.67 |
| ▸ | MEN1 | O00255 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | CASP3 | P42574 | 1/20 | 0.67 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.67 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.67 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.67 |
| ▸ | DDX3X | O00571 | 2/20 | 0.66 |
| ▸ | MAOA | P21397 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5852186 | 0.86 | DDX3X (0.70) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL812756 | 0.86 | DDX3X (0.80) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL1275926 | 0.84 | RAB9A (0.75) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL3460449 | 0.83 | DDX3X (0.70) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL17079606 | 0.83 | RAB9A (0.66) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL687547 | 0.83 | RAB9A (0.66) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL17079603 | 0.83 | DDX3X (0.79) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL6799221 | 0.82 | RAB9A (0.73) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL17079626 | 0.81 | RAB9A (0.73) | RAB9AKMT2ANPC1MEN1MAPT | |
| SCHEMBL16942599 | 0.81 | RAB9A (0.62) | RAB9AKMT2ANPC1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015136292-A9 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2022-04-21 | — | — | WO | disclosed |
| US-9884812-B2 | Use of DDX3X inhibitors for the treatment of pneumovirus infections | UNIVERSITY OF WARWICK (GB) | 2018-02-06 | — | — | US | disclosed |
| US-9884812-B2 | Use of DDX3X inhibitors for the treatment of pneumovirus infections | UNIVERSITY OF WARWICK (GB) | 2018-02-06 | — | — | US | disclosed |
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2017-06-15 | — | — | US | disclosed |
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2017-06-15 | — | — | US | disclosed |
| WO-2015136292-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | DDX3X, DDX1, DDX5 | RAB9A 873/4885KMT2A 2069/4885NPC1 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.